 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ARGX-119 / argenx
Trial completion date, Trial primary completion date: A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants (clinicaltrials.gov) - Nov 28, 2023
P1, N=116, Recruiting, Sponsor: argenx
Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
- ||| ARGX-119 / argenx
Enrollment open, Trial completion date, Trial primary completion date: A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants (clinicaltrials.gov) - Feb 8, 2023
P1, N=100, Recruiting, Sponsor: argenx
Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024 Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
- ||| ARGX-119 / argenx
New P1 trial: A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants (clinicaltrials.gov) - Jan 4, 2023
P1, N=100, Not yet recruiting, Sponsor: argenx